Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I. Haddad, Steven I. Sherman, Martin Schlumberger et al.|Endocrine|2017Cited by 104
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.Elena Garralda, Pilar Garrido, David R. Spigel et al.|Journal of Clinical Oncology|2024Cited by 2